Mangoceuticals, Inc. Common Stock

Day range

$0.22 – $0.23

Open

$0.23

Prev close

$0.23

Volume

171.94K

Market cap

$5.15M

Shares out

21.57M

P/E

—

P/S

12.33

P/B

0.38

P/FCF

—

ROE

-149.1%

ROA

-139.0%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Public offeringOct 9, 2026

  On October 8, 2026, Mangoceuticals, Inc. entered into a securities purchase agreement with certain investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering, 657,000 shares of common stock, common warrants to purchase up to 657,000 shares, and up to 788,400 shares issuable upon warrant exercise. Each Share and accompanying Warrant was sold at a combined offering price of $0.75, for aggregate gross proceeds of approximately $492,750.

• Deal withdrawalAug 21, 2026

  On August 19, 2026, Mangoceuticals, Inc. (the "Company" or "MGRX") and Nuclea Energy Inc. ("Nuclea") mutually agreed to terminate that certain Business Combination Agreement, dated as of July 29, 2026 (the "BCA")... Given that the PIPE Minimum Amount could not be raised on or prior to the Outside Date of August 21, 2026, the parties mutually determined that the financing conditions to closing could not be satisfied on the terms contemplated by the BCA.

• Listing deficiency noticeAug 4, 2026

  On February 4, 2026, Mangoceuticals, Inc. (the "Company") received a deficiency notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of the Company's common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial compliance period of 180 calendar days, or until August 3, 2026, to regain compliance with the minimum bid price requirement.

• Bylaw amendmentJul 30, 2026

  On July 28, 2026, the Board of Directors of the Company adopted an amendment to Section 3.8 of the Company's Bylaws (the "Bylaw Amendment"), effective immediately. The Bylaw Amendment reduces the quorum requirement for stockholder meetings from a majority of the voting power of issued and outstanding shares of stock entitled to vote to one-third (1/3) of the voting power of all issued and outstanding shares of stock entitled to vote.

• Private placementJul 2, 2026

  On June 29, 2026, Mangoceuticals, Inc. (the "Company", "we" and "us") entered into a Subscription Agreement with an accredited investor (the "Investor"), pursuant to which the Investor purchased 850,000 shares of restricted common stock from the Company, for $0.32 per share, or a total of $272,000. The Subscription Agreement included customary representations and warranties of the Investor and the Company and includes piggyback registration rights for a period of one year following the dates of the subscription.

Days to cover

1.0

Short interest

438.79K

Avg volume

655.31K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
  positiveGlobeNewswire Inc.· Oct 1, 2026
• Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
  negativeGlobeNewswire Inc.· Mar 17, 2026
• Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
  positiveGlobeNewswire Inc.· Mar 6, 2026
• Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
  positiveGlobeNewswire Inc.· Nov 13, 2025
• Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division
  positiveGlobeNewswire Inc.· Apr 25, 2025